Canaccord lowers Helus Pharma stock price target on valuation

Canaccord cut its Helus Pharma (HELP) price target to $42 from $45 but kept a Buy rating, citing HLP003’s Phase 3 program for major depressive disorder (APPROACH 88% enrolled) with top-line data expected in Q4 2026. The company also closed a $50M underwritten offering and a separate public offering of 10M+ shares at $4.85/share, with proceeds earmarked for the next Phase 3 trial (EMBRACE) and a potential U.S. FDA NDA targeted for 2028. Shares have jumped nearly 30% over the past week, but the stock’s recent financing and narrative sensitivity to forthcoming Phase 3 data keep the outlook cautious.

Analysis

HELP is trading less like a clinical-stage biotech and more like a financing-and-governance story. The recent capital raises reduce near-term survival risk, but they also reset the shareholder base and cap upside until the market sees whether management can convert enrollment progress into a credible data path; in CNS, the discount rate is driven by execution quality, not milestone optics. The immediate beneficiaries of the sector tape are liquid psychedelic proxies and any names with nearer catalysts; HELP is actually disadvantaged because its main readout is still far away, so momentum can decouple from fundamentals for months.

The biggest second-order issue is dilution overhang. After repeated financings, each incremental dollar raised lowers the chance of a scarcity premium, which means rallies can fade faster than in better-capitalized peers; the stock may need either a credible biopharma CEO hire or a strategic partner to rerate. Over the next 1-3 months, the market is likely to treat HELP as an option on 2026 rather than a core asset, keeping valuation compressed despite sector enthusiasm.

Contrarianly, consensus may be overestimating how much broad psychedelic optimism can lift this name. The far-out NDA timeline leaves little fundamental support for a durable rerating today, and psychiatry trials remain noisy even when enrollment looks clean; the eventual data quality matters far more than incremental enrollment progress. What would break the bearish framing is a respected CEO, no further equity issuance, and continued clean enrollment into mid-2026; absent that, upside is more tactical than structural.

Key Decisions for Investors

• Do not chase HELP common after the recent spike; wait for a pullback or a post-rally consolidation before considering any long entry. Falsifier: a credible biopharma CEO appointment plus no follow-on financing would justify revisiting the long.
• For relative-value exposure to the psychedelic theme, consider long PSIL versus short HELP over the next 1-3 months. This captures sector beta while hedging HELP-specific dilution and governance risk; cover if HELP secures a high-quality CEO or partnership.
• If you need downside expression, use 2-4 month HELP put spreads on strength rather than outright shorting. The trade is best sized as a tactical fade of the recent rerate, with downside targeted to the pre-surge support zone.
• Set alerts for two catalysts: a new CEO announcement and any additional equity filing. If neither occurs within ~60 days, treat the stock as a financing story first and a pipeline story second.